OWC Partners With G.C. Group to Develop Cannabinoid-Based Formulations and Delivery Methods for Several Medical Indications
22 Apr, 2015, 08:00 ET
PETACH TIKVA, Israel, April 22, 2015 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), developer of cannabinoid-based therapies and consulting services to governments, today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company"), has entered into agreement with G.C. Group to develop new formulations and delivery methods targeting several medical indications.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
Under the terms of the agreement, G.C. Group Ltd., an Israeli pharmaceutical R&D company engaged in development of variety of innovative and generic drug products of different types, will develop cannabinoid-based oil formulations that will be tested with unique delivery methods. One World Cannabis will continue its research and development efforts aimed at identifying cannabinoid-based therapies targeting a variety of different indications that incorporate the delivery methods.
One World Cannabis will continue to collaborate with other industry partners, as well as leading academic medical centers, in order to develop, clinically research, produce, and commercialized novel cannabinoid-based therapies targeting a variety of different indications and effectively help patients in need.
"We are very excited to about the work we are doing with the experts at G.C. Group," said Dr. Yehuda Baruch, Director of Research and Regulatory Affairs of One World Cannabis. "This collaboration acknowledges our focused research efforts not only on novel formulations of cannabinoid-based therapies, but also on novel delivery mechanisms."
About One World Cannabis Ltd.
One World Cannabis Ltd. ("the Company") is an Israel-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis (marijuana) treatment and medical cannabis regulatory affairs. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Ziv Turner, CEO
One World Cannabis Ltd. (OWC)
Email: [email protected]
SOURCE OWC Pharmaceutical Research Corp.
Share this article